Skadden Reps Valeant In $345M Jannsen Unit Buy
Canada-based Valeant Pharmaceuticals International Inc. said Friday it had agreed to acquire a Jannsen Pharmaceuticals Inc. dermatology unit for $345 million, capping off a $1 billion skin care drug buying spree...To view the full article, register now.
Already a subscriber? Click here to view full article